Improving livebirth rates: A role for preconception aspirin?

摘要

Failed implantation, fetal death, pre-eclampsia, fetal growth restriction, preterm birth, and placental abruption have all been linked to abnormal early placental development, thus, the potential to affect placental development and function to decrease such adverse pregnancy outcomes is an exciting focus of research in preconception and early pregnancy care. Daily low-dose aspirin given before 16 weeks' gestation to women at high risk of adverse pregnancy outcomes mitigates that risk, whereas starting treatment after 16 weeks does not. In a meta-analysis, Villa and colleagues reported that low-dose aspirin started before 16 weeks' gestation reduced the frequency of pre-eclampsia in high-risk women. Jim Thornton asserts that there is no further question about the effectiveness of low-dose aspirin started during pregnancy in decreasing some adverse outcomes in high-risk women.